Quick Answer
OnKure Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $59.05 million for the year ending 2025.
- OnKure Therapeutics, Inc. showed a decrease of -46.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from OnKure Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $91.22 million | Q2 2021: $140.37 million | Q3 2021: $126.41 million | Q1 2022: $121.09 million | Q2 2022: $118.26 million | Q3 2022: $62.13 million | Q1 2023: $30.40 million | Q2 2023: $9.08 million | Q3 2023: $11.74 million | Q1 2024: $20.38 million | Q2 2024: $35.97 million | Q3 2024: $60.69 million | Q1 2025: $96.66 million | Q2 2025: $83.37 million | Q3 2025: $70.33 million.
- Over the full 6 years of available data (2020 to 2025), OnKure Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 10.1%.
- Historical annual values: Fiscal year 2025: $59.05 million | Fiscal year 2024: $110.76 million | Fiscal year 2023: $29.88 million | Fiscal year 2022: $19.93 million | Fiscal year 2021: $124.66 million | Fiscal year 2020: $53.61 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: